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Abstract
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Because of a soaring number of opioid-related deaths during the past decade, opioid use disorder
has become a prominent issue in both the scientific literature and lay press. Although most of the
focus within the emergency medicine community has been on opioid prescribing—specifically, on
reducing the incidence of opioid prescribing and examining alternative pain treatment—interest is
heightening in identifying and managing patients with opioid use disorder in an effective and
evidence-based manner. In this clinical review article, we examine current strategies for
identifying patients with opioid use disorder, the treatment of patients with acute opioid
withdrawal syndrome, approaches to medication-assisted therapy, and the transition of patients
with opioid use disorder from the emergency department to outpatient services.

INTRODUCTION

Author Manuscript

Opioid misuse is a major public health emergency in the United States, affecting
communities large and small, urban and rural, affluent and poor.1,2 The opioid epidemic is
unique in its vast reach, and a rapid increase in opioid-related deaths has led to declarations
of a national crisis, with urgent calls to focus on evidence-based strategies to curb the
epidemic and increase federal funding for treatment programs and opioid abuse-related
research.3
*
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According to the 2015 National Survey on Drug Use and Health, an estimated 3.8 million
individuals, composing 1.4% of the US population aged 12 years and older, were current
misusers of pain relievers.4 An additional 329,000 people aged 12 years and older use
heroin. During the same year, more than 2.1 million individuals initiated the inappropriate
use of prescription pain medications, and nearly 135,000 became new heroin users.5 There
were 63,632 drug overdose deaths in 2016, representing a 21.4% increase from 2015.6
Furthermore, 66.4% of drug overdose deaths involved an opioid (illicit, prescription, or
both), an increase of 27.7% from 2015.7 Since 2000, there has been a 200% increase in the
rate of opioid overdose deaths, with heroin and synthetic opioids other than methadone
considered the primary drivers.8

Author Manuscript

Within the US health care system, emergency departments (EDs) are often at the forefront of
the opioid epidemic, treating individuals with opioid overdose, complications from opioid
use, or long-term opioid addiction.7 To date, much of the focus within the emergency
medicine community has been on opioid prescribing patterns, addressing concerns that
physician prescribing may be an important driver of opioid abuse, dependence, and
overdose.9 Since 2012, the American College of Emergency Physicians (ACEP) has
promoted an opioid prescribing policy that encourages the use of nonopioid analgesics to
treat pain when appropriate.10,11 However, ED prescribing reflects less than 5% of total
opioid prescribing in terms of the total quantity of opioids in morphine equivalents.12

Author Manuscript

There is significantly less emphasis on establishing best practices for transitioning patients
with opioid use disorders from the ED to appropriate longitudinal services and development
of evidence-based treatment strategies. Furthermore, the Center for Behavioral Health
Statistics and Quality recognizes that many patients with substance use disorders, including
opioid use disorder, are not receiving treatment and many of these patients are not seeking
treatment in traditional inpatient treatment centers.4 Expanding the availability of
medication-assisted therapy and facilitating entry into appropriate outpatient treatment
centers is a critical step in addressing this treatment gap.
This article examines the current body of evidence underpinning the identification of
patients at risk for opioid use disorder, ED-based symptomatic treatment of acute opioid
withdrawal, medication-assisted treatment of opioid use disorder on discharge from the ED,
and transition to outpatient services.
Screening for Opioid Use Disorder in the ED

Author Manuscript

Emergency physicians require screening tools to identify patients with opioid use disorder,
as well as those at risk for opioid-related harms, including overdose and misuse. Screening
tools must be accurate, reliable, and easy to administer in the ED environment. They also
must be brief and integrate seamlessly into existing ED work flows to promote widespread
uptake and use.13 Competing clinical care priorities, limited time, and staff turnover present
significant challenges to screening in a busy ED environment. Although many opioid
screening tools have been validated, not all have been examined in the ED environment, and
therefore generalizability should be examined before their use in the ED.
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Table 1 provides an overview of commonly used screening tools for opioid abuse, misuse,
and dependence. The Opioid Risk Tool is a self-report screening tool developed to assess the
likelihood of opioid misuse among patients with chronic pain. It was initially tested and
validated in patients presenting to a pain management clinic before initiation of prescription
opioid therapy.14 The Current Opioid Misuse Measure and the Addiction Behaviors
Checklist were both developed and validated in a pain clinic setting to clarify aberrant drugrelated behavior in a population of patients already receiving long-term opioid therapy.15,16

Author Manuscript

Likewise, the Revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R)
was also initially developed and validated in a cohort of individuals seeking outpatient care
for chronic pain before receiving opioid therapy.17 The SOAPP-R is a 24-question
assessment, longer than most other drug and alcohol screening tools used in ED setting.
However, SOAPP-R correlates highly with opioid use disorder in the ED setting, and
another study demonstrated the ability to administer SOAPP-R through tablet computers in
the ED.18,19 The latter study found that most patients were able to complete the screening
tool in 5 minutes or less.19
The World Health Organization designed and validated the Alcohol, Smoking and Substance
Involvement Screening Test to detect substance use problems among primary care patients.
20 The National Institute on Drug Abuse developed the modified Alcohol, Smoking and
Substance Involvement Screening Test to address illicit opioid use, including heroin, and
misuse of prescription opioids.21 Although evidence is limited, use in ED research settings
demonstrates the tool’s ability to successfully identify patients with nonmedical prescription
opioid use and other substance use problems.22−24

Author Manuscript
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ACEP and others have suggested that statewide prescription drug monitoring programs may
also serve as an important screening tool to identify patients at risk for opioid misuse.25 At
the population level, states that implement a robust prescription drug monitoring program
realize significant reductions in opioid-related overdose deaths.26 However, the programs do
not capture data on patients who obtain opioids without a prescription, and there is no
current evidence that these programs alone are capable of identifying individual patients
with opioid use disorder. One recent study attempted to determine whether a combination of
SOAPP-R and use of a prescription drug monitoring program could predict which ED
patients being considered for discharge with an opioid prescription could be considered high
risk for abuse potential.27 Although the SOAPP-R has a high negative predictive value, the
sensitivity of this self-report tool for detecting high-risk behavior based on prescription drug
monitoring program criteria was low, suggesting that self-report tools and the prescription
drug monitoring programs provide important but different types of information and are best
used in tandem. Another study from a single academic urban medical center showed that
prescription drug monitoring programs were unable to detect many patients with selfreported opioid use disorder.28 Therefore, we do not recommend using the prescription drug
monitoring program alone to assess for risk for opioid use disorder. However, in
combination with self-reported data, the program may present complementary objective data
worth considering in the screening process.

Ann Emerg Med. Author manuscript; available in PMC 2019 July 08.

Duber et al.

Page 4

Author Manuscript

Finally, significant questions remain about whom to screen for opioid use disorder in the
ED. At present, no formal guidelines exist. In accordance with the current body of evidence,
we do not believe in the justification of universal screening, given a large number of
limitations to the currently available self-report screening tools. However, judicious use of
prescription drug monitoring programs when implemented in an effective and easy-to-use
manner, along with a targeted screening of at-risk individuals (eg, reported history of opioid
misuse, positive drug screen result) or of individuals who will be discharged with opioids, is
recommended and in fact mandated in many states.24,29 This is an area that requires further
investigation.
ED Management of Acute Opioid Withdrawal
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Abrupt discontinuation of long-term prescription or illicit opioids can produce withdrawal
symptoms as early as hours after the last use (eg, 3 to 5 hours after last fentanyl use, 6 hours
after last heroin use). Initial symptoms of anxiety, agitation, and restlessness are distressing
to patients, which may lead to increased irritability and aggression directed toward health
care providers. As a result, providers may be less empathetic toward their patients, often
unintentionally, further deviating from a therapeutic patient-provider relationship. Without
treatment, acute opioid withdrawal is likely to progress, and the patient may experience
excessive yawning, lacrimation, rhinorrhea, diffuse myalgias, abdominal cramping, nausea,
vomiting, diarrhea, and insomnia. Physical examination findings can include mydriasis,
tachycardia, hypertension, diaphoresis, and piloerection.30

Author Manuscript

Symptoms of acute opioid withdrawal are often poorly tolerated. Even when the severity of
concurrent medical conditions necessitates inpatient admission, patients experiencing acute
opioid withdrawal may choose to leave against medical advice if they believe there is no
prospect of pain relief.31 Symptomatic management of acute opioid withdrawal can improve
compliance with necessary treatment of concurrent medical or surgical conditions and
therefore improve health outcomes.32,33 Managing patient symptoms, along with
expectations, is key to caring for patients with acute opioid withdrawal.
Treatment of opioid withdrawal requires identification of symptoms and assessment of
clinical status. Several validated tools currently exist, including the Clinical Institute
Narcotic Assessment scale, the Short Opiate Withdrawal Scale, and the Clinical Opiate
Withdrawal Scale.34−36 Many experts consider the latter, an 11-item clinician-administered
scale assessing opioid withdrawal, to be the most useful evidence-based tool in the ED
setting. Its brevity and simplicity allow easy, rapid recognition of potential opioid
withdrawal syndromes and can assist clinicians in making treatment decisions.

Author Manuscript

Although acute opioid withdrawal is not typically life threatening, failure to address
withdrawal and the circumstances that may ensue from untreated opioid withdrawal can
result in morbidity and mortality.37 In particular, patients who have comorbid conditions,
such as coronary artery disease, congestive heart failure, insulin-dependent diabetes mellitus,
epilepsy, or liver failure, are at increased risk of death in cases of opioid withdrawal. This is
an important distinction from the historical teaching that opioid withdrawal is not dangerous,
often leading to neglect in addressing this potentially life-threatening situation. Whether
persons engage in dangerous criminal activity to obtain opioids or choose to forgo necessary
Ann Emerg Med. Author manuscript; available in PMC 2019 July 08.
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treatment for a serious medical condition, desperate actions they take to experience
symptom relief from acute opioid withdrawal can increase the risk of life-threatening harm
and death.
Below, we present options for targeted opioid withdrawal and management, as well as a
variety of other medications to consider for symptomatic opioid withdrawal treatment for
patients who do not require opioids for acute pain.
Buprenorphine

Author Manuscript

A partial μ-agonist with a long half-life (24 to 60 hours), buprenorphine has higher affinity
yet lower intrinsic activation at the μ-type opioid receptor than many full agonists, including
heroin, oxycodone, morphine, and methadone. Because buprenorphine will displace full
opioid agonists without providing the same degree of receptor activation, a sufficient period
after the last opioid use must transpire before administration of buprenorphine. Whether
initiating induction or treating acute withdrawal, physicians should not administer
buprenorphine until moderate symptoms of opioid withdrawal have developed. When
administered before the onset of withdrawal, buprenorphine can precipitate moderate opioid
withdrawal symptoms. The period of abstinence required both before induction and acute
withdrawal treatment will vary in part as a function of the half-life of the opioid last used.
Expect spontaneous withdrawal to occur within 6 to 12 hours in the case of short-acting
opioids such as heroin and oxycodone, and within 24 to 72 hours for opioids with longer
half-lives such as methadone.
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Traditional teaching is that after an initial sublingual dose of 2 to 4 mg of buprenorphine, a
60- to 90-minute observation period is necessary to ensure that withdrawal symptoms
improve.39 If symptoms persist, dose titration in 2- to 4-mg increments may be necessary to
achieve clinical effectiveness. A maximum initial daily dose of 8 to 12 mg of buprenorphine
is formally recommended.40 Nonopioid medications can be used to manage residual
withdrawal symptoms. However, individual providers with significant experience managing
opioid withdrawal have found that initiating treatment with higher doses of buprenorphine
(eg, 8 mg), more rapid titration (eg, 8-mg increments), and a higher 24-hour maximum dose
may be required in some patients with heavy routine opioid use. Simultaneously, given
buprenorphine’s partial agonist mechanism of action, there is a “ceiling effect” whereby
higher doses of the medication may not lead to additional receptor activation and desired
effect.40,41 This results in a more favorable adverse effects profile compared with that of
methadone and other opioid receptor agonists. Additional information on the requirements
for prescribing opioids in the ED and the initiation of medication-assisted therapy is
described below.
Buprenorphine is commonly paired with naloxone in the sublingual form to prevent abuse.
Naloxone has a low bioavailability when taken orally, but if the tablets are dissolved and
injected, the antagonist effects of naloxone will predominate, limiting abuse potential.
However, the combined medication should not be provided to pregnant patients because fetal
exposure to naloxone may precipitate withdrawal. Buprenorphine without naloxone is safe
in pregnancy and, for compliant mothers, is associated with milder neonatal abstinence
syndrome than in the neonates of mothers managed with methadone.42
Ann Emerg Med. Author manuscript; available in PMC 2019 July 08.
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Patients already enrolled in a methadone treatment program can continue to receive
methadone treatment in the ED when being admitted to the hospital to prevent and treat
acute methadone withdrawal. Methadone is a long-acting μ-agonist (full agonist) with a
mean half-life of approximately 8 to 59 hours in adults. Methadone is also safe during
pregnancy. The recommended starting dose is tailored to the patient’s opioid use history,
concomitant substance abuse, previous experience with methadone, and other psychiatric
and medical comorbidities.43 Adverse effects include QT-interval prolongation, and caution
should be taken when combining methadone with other QT-interval-prolonging medications,
such as ondansetron. Additionally, methadone is metabolized by the cytochrome P450
enzyme system of the liver and should be used with caution in patients with liver disease,
concomitant use of cytochrome P450 inducers, or concomitant use of medications with the
potential for hepatotoxicity.32

Author Manuscript

Clonidine
Albeit considered an off-label use of this α2-adrenergic agonist, research demonstrates the
effective use of clonidine in controlling acute opioid withdrawal symptoms and lessening the
likelihood of severe withdrawal.44 The recommended dose is 0.1 mg orally every 6 hours
until symptoms resolve, up to a maximum starting dose of 0.4 mg during a 24-hour period.
Transdermal clonidine patches may also be considered. Adverse effects include bradycardia
and hypotension, and one should consider hemodynamic monitoring when administering
intravenous clonidine.31 Clonidine alone may not be as effective as other monotherapies for
the treatment of severe acute opioid withdrawal and therefore is often used in conjunction
with μ-agonist therapy.45
Other Symptomatic Opioid Withdrawal Treatment

Author Manuscript

In addition to targeted opioid withdrawal treatment, symptom management can also bring
comfort to patients presenting to the ED with acute withdrawal. In the case of excessive
vomiting and diarrhea, standard ED resuscitation of a volume-depleted patient with
crystalloid fluids is appropriate. Monitoring of electrolytes and appropriate repletion may be
required in patients with evidence of moderate to severe dehydration. Table 2 presents
commonly used medications for the symptomatic treatment of opioid withdrawal, as well as
possible adverse effects.

TRANSITIONING PATIENTS FROM THE ED
Medication-Assisted Therapy

Author Manuscript

In 2015, the American Society of Addiction Medicine published the “National Practice
Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,”
which was intended to provide information on evidence-based treatment of opioid use
disorder.30 Medication-assisted therapy is a term that refers to any addiction treatment that
includes the use of pharmacologic treatments. For opioids, such therapy uses pharmacologic
properties of medications that act as agonists, partial agonists, or antagonists of the μ-type
opioid receptor, including methadone, buprenorphine, and naltrexone. When methadone is
used as medication-assisted therapy, follow-up care can be provided to patients only by an
opioid treatment program that offers supervised dosing and is required to include elements
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of a psychosocial intervention.38,46 When buprenorphine is used as medication-assisted
therapy, follow-up care can be obtained through opioid treatment programs, hospitals, health
departments, and other qualified providers, as detailed below.
Medication-assisted therapy improves long-term outcomes for patients with opioid use
disorder. Specifically, patients who receive opioid agonist therapy as part of treatment for
opioid use disorder have a decreased chance of fatal overdose compared with those who
receive psychological counseling alone.47 Furthermore, patients receiving maintenance
buprenorphine for at least a year require fewer ED visits and hospitalizations compared with
those who discontinue buprenorphine. Thus, early initiation and maintenance of medicationassisted therapy can significantly affect health care use and improve wellness for patients
with opioid use disorder.48

Author Manuscript
Author Manuscript

Initiation of buprenorphine for patients with opioid use disorder in the ED is efficacious and
safe. In a seminal study, D’Onofrio et al49 evaluated the efficacy of ED initiation of
buprenorphine in patients with opioid use disorder compared with brief behavioral
counseling alone or usual care. Patients who met Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV)criteria for opioid dependence (replaced in
DSM-5 by opioid use disorder) and had a urine specimen that tested positive for opioids
were randomized to one of the treatment arms. Individuals randomized to the buprenorphine
group were further assessed for withdrawal with the Clinical Opiate Withdrawal Scale. If a
patient with opioid use disorder had symptoms consistent with moderate to severe opioid
withdrawal, he or she was provided with a dose of buprenorphine in the ED, as well as a
prescription for enough medication to last until a follow-up primary care appointment could
take place within 72 hours of discharge. Patients not in active withdrawal were instructed to
begin receiving buprenorphine once symptoms of moderate withdrawal developed and,
likewise, were provided with a prescription and primary care follow-up in the hospital’s
clinic that had established protocols within 72 hours. At 30 days after ED discharge, patients
randomized to ED initiation of buprenorphine were more likely to be engaged in addiction
treatment and had less illicit opioid use per week than those randomized to either brief
behavioral counseling alone or usual care. These differences remained significant 2 months
after the ED visit when primary care physicians continued buprenorphine in outpatient
clinics.50 Furthermore, medication-assisted therapy initiated in the ED was found to be costeffective compared with referral to community-based treatment, further supporting ED
initiation of buprenorphine for patients with opioid use disorder when treatment can be
continued in an outpatient office setting.51

Author Manuscript

Prescribing buprenorphine can present a number of challenges and requires careful
consideration. First, the Drug Addiction Treatment Act of 2000 (DATA 2000) created a
special licensing system for physicians to prescribe opioid-based medications to treat
addiction.52 To obtain a Drug Enforcement Administration × license, or “DATA 2000
waiver,” a physician must complete an 8-hour training program either online or in person.53
Participants receive training on identifying appropriate candidate patients for buprenorphine
treatment, how best to use medications in addiction treatment, and how to apply for the
waiver to prescribe.53 The Drug Enforcement Administration also provides guidance to
practitioners without a waiver in emergency situations. Specifically, physicians who have not
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completed the training and do not hold a DATA 2000 waiver can administer opioid
medications (including buprenorphine) to a patient to relieve acute withdrawal symptoms
while arranging for a referral to addiction treatment. This treatment can be administered
only in the ED during 72 hours, and additional doses cannot be dispensed or prescribed
without the appropriate waiver.54 Under the so-called 72-hour rule (21CFR, Part
1306.07[b]), either buprenorphine or methadone can be dispensed, not prescribed, as an
induction or bridge medication from the ED up to 3 consecutive days while arrangements
are made for referral to treatment. To our knowledge, there are no published trials evaluating
the safety and efficacy of dispensing methadone to initiate medication-assisted therapy from
the ED, and thus buprenorphine is most often used in this practice.

Author Manuscript
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Patients under consideration for medication-assisted therapy should be evaluated to ensure
that they meet criteria for opioid use disorder. Additionally, comorbidities including
polysubstance use, current methadone use, and chronic pain requiring high daily doses of
opioids are also important factors to consider before buprenorphine treatment is embarked
on. Physicians with a DATA 2000 waiver can decide whether it is appropriate to initiate
buprenorphine treatment at home or in the ED. Home induction of buprenorphine is an
acceptable treatment strategy used by many physicians and can decrease the need for lengthy
ED visits when a patient is not in withdrawal. Regardless of whether a patient receives
medication-assisted therapy, supplying or prescribing naloxone rescue kits for all opioid use
disorder patients, and counseling them on proper kit use, can be lifesaving, given their
elevated risk of accidental overdose. This important harm reduction measure is well studied,
effective, and supported by ACEP.55,56 Finally, any patient receiving ED initiation of
buprenorphine should ideally be discharged with a streamlined plan for prompt follow-up in
an outpatient clinic or addiction treatment facility to ensure continued medication-assisted
therapy induction, stabilization, and long-term maintenance management of opioid use
disorder. Treatment with buprenorphine in the ED does not preclude transitioning patients to
methadone therapy as part of a comprehensive outpatient treatment plan.
Linkage to Treatment

Author Manuscript

Coordinated care for complex chronic conditions has repeatedly shown marked positive
influence on disease trajectory.57,58 The treatment of opioid use disorder is no different, and
a coordinated transfer of patient care to the outpatient setting has received increased
attention.38,59,60 However, EDs face significant challenges in referring patients with opioid
use disorder in a timely and coordinated fashion. Opioid use disorder treatment is often
disconnected from the acute care health care system, and very few programs have competent
referral mechanisms that can be accessed by an emergency physician. This disconnect places
ED providers in a challenging position when attempting to care for patients with opioid use
disorder. Although providers may be able to identify serious illness requiring specialty
follow-up, EDs may not have the mechanisms or resources to ensure appropriate linkage to
care.
In general, a comprehensive treatment strategy for patients with opioid use disorder involves
3 components: medication-assisted therapy, psychological interventions, and social support
or case management. Although each has its own utility, a strategy combining all 3 is likely to
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be more successful in achieving lasting effects, especially in patients with severe injection
opioid use disorder.61 As noted above, medication-assisted therapy has been shown to be
safe when initiated in the ED, and consideration should be given to doing so. This is
particularly true if appropriate follow-up services can be arranged. Psychological therapy
may come in many forms, from individual psychosocial interventions to group or family
therapy. Additionally, psychological therapy can be complemented by psychiatric care,
depending on the presence and severity of other mental health conditions. Finally, social
support and case management services help ensure that patients complete evaluation and
treatment programs through improved navigation of social situations and overcoming of
potential barriers to care, leading ultimately to a successful recovery. The concept of peer
support or recovery coaching is one proposed support system, although others exist, and
more evidence is generally needed in regard to the efficacy of these programs.62,63

Author Manuscript

Ideally, outpatient treatment should begin as soon as possible and preferably within 72 hours
of ED evaluation. A rapid transition to outpatient care helps to ensure that patients receive
the necessary services, including medication-assisted therapy.64 To facilitate this process,
some institutions have developed a “bridge” clinic that assists with obtaining next-day
evaluations for continuation of therapy and ensuring that patients receive an appropriate
referral for opioid use disorder and associated comorbidity.65 However, it is recognized that
robust linkages to outpatient medication-assisted therapy are not available at many
institutions, and therefore providers and health care systems are encouraged to develop
reasonable outpatient follow-up plans.
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In addition to having appropriate and timely outpatient services available to ED patients with
opioid use disorder, the way in which patients are referred may have a considerable effect on
their long-term care. Traditionally, and in most communities today, there is little to no
communication between EDs and treatment programs. These “cold handoffs” often result in
delays in outpatient services, repeated assessments, gaps in medication-assisted therapy, and
overall worse outcomes.66 One strategy for improving coordination of care between the ED
and outpatient settings is a “warm handoff” between providers,67 which has been defined by
the Agency for Healthcare Research and Quality as “a handoff that is conducted in person,
between two members of the healthcare team, in front of the patient (and family if
present).”68 Although it may not always be possible or realistic to expect such handoffs to
occur in the ED environment, having a direct conversation with the outpatient team receiving
the patient may help alleviate some of the barriers in care and provide a more streamlined
transition process. In busy EDs, training and using allied health professionals (eg, social
workers) as important conduits in the transition process may improve the rate at which
communication with outpatient providers and clinics occurs. Although not all EDs will be
adequately resourced to perform warm handoffs, moving toward an improved system of
communication is likely to benefit patients.
During times when the outpatient treatment team may not be readily accessible (eg, nights,
weekends), hotlines or referral coordinators can help bridge communication gaps. Where
available, regional referral resources provide a mechanism by which patients can be linked
with outpatient providers capable of delivering comprehensive opioid use disorder treatment,
including medication-assisted therapy. Complicated assessment processes that delay
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appropriate access are challenging for patients to navigate and lead to poor follow-up
compliance. Referral coordinators must facilitate the most rapid entry to comprehensive
treatment possible and should be well trained in the overall management of opioid use
disorder.

Author Manuscript

The transition of care from the ED to the outpatient setting represents a high-risk period for
patients, and carefully coordinated care is essential to minimize the potential for acute
opioid withdrawal and relapse. Outpatient services should be able to provide medicationassisted therapy, often after it has been initiated in the ED. Furthermore, clinics should be
capable of providing or coordinating the appropriate counseling and social services, both of
which are likely to lead to improved compliance and better health outcomes. Finally, a rapid
referral system is essential because delays are likely to result in poor follow-up rates. Warm
handoffs and regional referral systems are 2 mechanisms by which communication between
the ED and outpatient providers can be improved and rapid entry into long-term treatment
achieved.

CONCLUSION

Author Manuscript

In addition to providing high-quality acute care around the clock, EDs also function as a key
entry point into the health care system for many patients. This is particularly true for
vulnerable populations with poor access to care, including many individuals with opioid use
disorder. Uniquely situated on the front lines of the opioid epidemic, EDs treat opioid
overdoses, as well as the complications of opioid use disorder and long-term addiction daily.
As the opioid epidemic continues, EDs will play an integral part in mitigating the human toll
on many levels through screening and identification of patients at risk for opioid use
disorder, managing acute opioid withdrawal, initiating medication-assisted therapy, and
coordinating linkage to outpatient treatment. However, much work remains to be done to
create, validate, disseminate, and implement effective evidence-based strategies to
accomplish these challenging tasks within the unique care environment of the ED.
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Future research will need to focus on more than opioid prescribing and alternative pain
management strategies in the ED. Specifically, more work is required to identify which
patients to screen, what tools to use, and what technology can be leveraged (eg, portable
electronic devices, waiting room kiosks) to adequately assess opioid use disorder risk while
minimizing the effect on ED patient turnaround times and ED provider workload.
Additionally, ED initiation of buprenorphine is safe and efficacious, and EDs should
consider how such a treatment program with aggressive linkages to an outpatient
medication-assisted therapy program could be initiated in their setting. Ongoing,
multicenter, randomized trials will assess for safety and generalizability to both academic
and community ED settings and provide information on the best implementation strategy for
this evidence-based treatment. Future clinical studies fielding the use of novel opioid use
disorder treatment agents, including pharmacology and vaccines, need to include ED patient
populations. Finally, the effect of a coordinated systems-based approach to treating opioid
use disorder, spanning the ED to the outpatient setting, needs to be evaluated rigorously in
large, pragmatic trials.
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EDs will continue to care for patients with opioid overdoses, complications of opioid
misuse, and chronic addiction. National calls to declare the opioid epidemic a public health
emergency and rapidly increase treatment capacity across the United States must include and
engage the emergency medicine community. A robust infrastructure to support, educate, and
enable emergency physicians to manage opioid use disorder in an evidence-based fashion
and rapidly transition care to outpatient services is a necessary step in turning the tide
against an opioid epidemic affecting communities nationwide.

RECOMMENDATIONS
The Figure presents an overview of the ED screening, treatment, and referral cascade for
patients with suspected opioid use disorder. In addition, we provide the following
recommendations:
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1.

Author Manuscript

2.

Author Manuscript

3.

Consider targeted screening of individuals at risk (eg, history of opioid misuse,
positive drug screen result) for opioid use disorder. We do not recommend
universal screening.
a.

All current opioid use disorder screening tools have some weakness. Of
the tools currently available, we recommend using the SOAPP-R or
National Institute on Drug Abuse-modified Alcohol, Smoking and
Substance Involvement Screening Test given before testing and
feasibility in the ED setting.

b.

ED providers should use the prescription drug monitoring program
when prescribing opioids and consider it as an adjunct tool when
screening for opioid use disorder.

We recommend treating acute opioid withdrawal in symptomatic ED patients
with opioid use disorder who are not receiving long-term opioid therapy for pain.
a.

Consider buprenorphine in patients with moderate withdrawal
symptoms.

b.

Patients already receiving methadone or buprenorphine treatment in the
outpatient setting should continue receiving these therapies after
confirmation of current doses.

c.

Nonopioid medications should be used as needed for symptomatic
treatment of acute withdrawal.

d.

All ED patients with acute opioid withdrawal should be considered for
medication-assisted therapy and provided appropriate follow-up.

We recommend that ED-initiated medication-assisted therapy be considered for
all patients with opioid use disorder.
a.

Buprenorphine should be considered the medication of choice when
medication-assisted therapy is initiated in the ED.

b.

All ED patients with identified opioid use disorder should receive a
naloxone rescue kit, or a prescription for such a kit, and be counseled
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about proper kit use regardless of whether medication-assisted therapy
is initiated.
4.

We recommend the development of systems of care that facilitate the transition
of patients with opioid use disorder from the ED to the community setting.
a.

When possible, warm handoffs are the preferred method of transition.

b.

Outpatient settings should be able to continue or initiate medicationassisted therapy, provide psychological interventions, and offer social
support or case management.
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Figure.

ED screening, treatment, and referral for opioid use disorder. OUD, Opioid use disorder;
MAT, medication-assisted therapy; PCP, primary care physician.
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20 questions (yes, no).

Adult patients with chronic pain
already prescribed opioids or sedative
analgesics.
Adults with no history of substance
use, history of use, and history of
dependence.

Intended for adults in the primary care
setting. Used effectively in the ED.

Wu (2006)16

WHO (2002)20
NIDA21
Blow (2017)22
Bogenschutz (2014)23
MaciasKonstantopoulos
(2014)24

Addiction Behaviors
Checklist (ABC)

Alcohol Smoking and Substance
Involvement Screening Test
(ASSIST V 3.0)

NIDA-Modified Alcohol,
Smoking and Substance
Involvement Screening Test
(NIDA-m-ASSiST)

NIDA, National Institute on Drug Abuse.

17 items, patient
selfassessment.
Likert 5-point scale.

Adult noncancer chronic pain patients.
Assesses risk for aberrant drug-taking
behavior before the initiation of opioid
therapy—chronic pain patients.

Butler
(2008)15

Current Opioid Misuse Measure
(COMM)

Patient interview or online
self-assessment.

Interviewer-administered
pencil-and-paper
questionnaire and screens.

Self-report, 24 questions.
Likert 5-point scale
(“never” to “very often”).

Adult patients with chronic noncancer
pain treated at pain clinics. Assessed
for feasibility in the ED.

Butler (2008)17
Reyes-Gibby (2016)18
Weiner (2015)19

Revised Screener and Opioid
Assessment for Patients With
Pain (SOAPP-R)

Brief self-report,
10 questions (yes, no).

Methods

Newly enrolled adult patients at a pain
clinic. Administered before beginning
of opioid therapy for pain
management.

Population

Webster (2005)14

Author

Opioid Risk Tool (ORT)

Tool

Author Manuscript

Opioid use disorder screening tools.

Patients are asked about street opioids, such as heroin, and
misuse of prescription opioids separately. Has not been
validated.

Addresses multiple addictive substances, including opioids.
Sensitivity and specificity developed for use/abuse and abuse/
dependence. Sensitivity 0.75, specificity 0.65 (for abuse/
dependence).

Assesses addictive behaviors exhibited “since the last visit” and
“within the current visit.”
Longitudinal assessment. Sensitivity 0.88, specificity 0.86 (using
a cutoff score of 3).

Sensitivity 0.77, specificity 0.68 (using a cutoff score of 9).

Short (95% completed in <5 min), easy to score, assessed in the
ED setting. Sensitivity 0.81, specificity 0.68 (using a cutoff
score of 18).

Assesses personal and family history of substance abuse, H/O
sexual abuse, and psychological disease.

Screening Tool Characteristics
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Ondansetron
Acetaminophen, ibuprofen
Trazodone

Pain

Insomnia

Famotidine

Dyspepsia
Methocarbamol

Loperamide

Diarrhea

Nausea/vomiting

Diazepam, hydroxyzine

Myalgias

Dicyclomine

Anxiety/restlessness

Medication

Abdominal cramps

Symptom

Orthostatic hypotension

Allergic reaction

QT-interval prolongation

Dysphoria and suicidal thoughts with higher doses

QT-interval prolongation

Torsades de pointes and cardiac arrest with higher doses

Oversedation (use caution when administering benzodiazepines in conjunction with μ-agonists)

Anticholinergic, dizziness, nausea

Common/Dangerous Adverse Effects

Nonopioid pharmacologic treatment options for symptomatic treatment of opioid withdrawal.
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